Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCT02540954 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Sponsor

Bayer